The CGT Strategic Reset: Why Science is Outpacing the Market
- Tina Witte
- 3 days ago
- 3 min read
The Reality of Rare Disease Management
We recently marked Rare Disease Day, a vital moment for the community. For those impacted by rare pathologies, the journey is often defined by a grueling "diagnostic odyssey," complex symptom management, and the constant hurdle of managed care coverage.
For many, cell and gene therapy (CGT) represents the ultimate beacon of hope—offering not just chronic disease management, but the potential for curative outcomes.
The Regulatory Paradox
As CGTs progress through the pipeline, the most promising assets often leverage expedited pathways—such as Orphan Drug Designation, Fast Track, or Accelerated Regulatory Reviews—to reach the market. However, despite this regulatory "fast lane," the CGT class is currently standing at a strategic crossroads.
Within the past year, we’ve seen industry giants like Pfizer and Takeda take significant steps back from the space.
Pfizer discontinued several genomic efforts and divested early-stage programs to Alexion.
Takeda moved away from its gamma-delta T-cell platform, resulting in a ¥58 billion write-down and significant layoffs at its Massachusetts R&D site.
The Commercial Friction: Why Big Pharma is Re-evaluating
Why the sudden retreat? It isn’t a failure of science; it is a case of the market not being ready to reward it.
The commercial and competitive realities of CGT are forcing a total rethink of the "blockbuster" model. For example, Pfizer’s hemophilia B therapy, Beqvez, faced significant headwinds despite its clinical promise. With a $3.5 million price tag and low physician uptake, it highlighted a stark reality: having a breakthrough drug is meaningless if the healthcare infrastructure cannot absorb the cost.
The Tension Between Cost and Value
The healthcare system is built on incremental costs, but CGTs demand a massive, "one-and-done" front-loaded payment. This creates a friction point for payers who must manage immediate budget hits for value that is realized over a decade.
Beyond the financials, the logistical complexity is immense:
Provider Burden:Â Preparing patients for intense myeloablative conditioning regimens.
Manufacturing Hurdles: The intricate "vein-to-vein" process of harvesting and amplifying a patient’s own cells.
Uncertain Durability:Â Long-term uncertainty regarding how long these therapeutic benefits will actually last.
The Verdict:Â The science is advancing faster than the payment models, care pathways, and operational systems designed to deliver it.
A Global Strategic Dilemma
While the U.S. leads in approvals, it remains the most fragmented reimbursement environment. Meanwhile, Europe’s Health Technology Assessment (HTA) rigor has pushed several therapies off the continent entirely. This creates a dilemma for manufacturers: Do you build a global infrastructure for a modality with uncertain returns, or narrow your bets and wait for policy to stabilize?
A Strategic Path Forward: How CGTs Can Thrive
The CGT category is far from stalled, but it is entering a "shakeout" phase. Success now requires a shift from product-centric thinking to system-level strategy. To thrive, organizations must prioritize three strategic pillars:
Innovative Reimbursement:Â Moving toward installment-based models and outcomes-based contracts to de-risk the cost for payers.
Delivery Infrastructure:Â Investing in "Centers of Excellence" and streamlined referral pathways to reduce friction for providers.
Real-World Evidence (RWE):Â Using longitudinal data to prove long-term durability, which is the key to unlocking broader access.
Elevate Your Competitive Advantage
The strategic path forward belongs to companies that view CGT as a systemic challenge, not just a clinical one.
Fletcher’s Life Science Practice holds over two decades of experience in the rare and orphan disease sector. If you are navigating the complexities of advanced therapeutics, let us help you apply Competitive Intelligence to stay ahead of the curve.
Ready to optimize your CI strategy? Contact Tina Witte, SVP of Life Sciences, today to explore how our team can help you anticipate market shifts and secure a clinical-to-commercial win.